-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JxzZhVk3vgco4yfEqK9AMtA0z+MJpnZ98L1wGfoh/hHaZWxzfn9gyZeutS7vL1d9 /Rg6SERXyaKSNTykKR2LiA== 0001193125-09-021407.txt : 20090206 0001193125-09-021407.hdr.sgml : 20090206 20090206172129 ACCESSION NUMBER: 0001193125-09-021407 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090206 DATE AS OF CHANGE: 20090206 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BARRIER THERAPEUTICS INC CENTRAL INDEX KEY: 0001173657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223828030 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79875 FILM NUMBER: 09578237 BUSINESS ADDRESS: STREET 1: 600 COLLEGE ROAD EAST STREET 2: SUITE 3200 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6099451200 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: DEVON PARK BIOVENTURES LP CENTRAL INDEX KEY: 0001356034 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 435 DEVON PARK DRIVE STREET 2: 700 BUILDING CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 6109777532 MAIL ADDRESS: STREET 1: 435 DEVON PARK DRIVE STREET 2: 700 BUILDING CITY: WAYNE STATE: PA ZIP: 19087 SC 13G/A 1 dsc13ga.htm SCHEDULE 13G AMENDMENT NO. 1 Schedule 13G Amendment No. 1
CUSIP No. 06850R108    Page 1 of 5

 

OMB APPROVAL

OMB Number:

    3235-0145

Expires:

    February 28, 2009

Estimated average burden

hours per response

  10.4

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

 

 

BARRIER THERAPEUTICS, INC.

(Name of Issuer)

 

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

 

06850R108

(CUSIP Number)

 

 

December 31, 2008

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

þ Rule 13d-1(c)

¨ Rule 13d-1(d)

 

 

*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes in the Form of Schedule 13G).


CUSIP No. 06850R108    Page 2 of 5

 

  1  

NAME OF REPORTING PERSON

 

Devon Park Bioventures, L.P.

   
  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)  ¨

(b)  x

   
  3  

SEC USE ONLY

 

   
  4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

   

 

NUMBER OF  

SHARES  

BENEFICIALLY  

OWNED BY  

EACH  

REPORTING  

PERSON  

WITH  

 

 

  5    SOLE VOTING POWER

 

       -0-

 

  6    SHARED VOTING POWER

 

       -0-

 

  7    SOLE DISPOSITIVE POWER

 

       -0-

 

  8    SHARED DISPOSITIVE POWER

 

       -0-

  9  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

-0-

   
10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 

 

¨

 

11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

-0-

   
12  

TYPE OF REPORTING PERSON*

 

PN

   

 


CUSIP No. 06850R108    Page 3 of 5

 

Item 1(a) Name of Issuer:

Barrier Therapeutics, Inc.

 

Item 1(b) Address of Issuer’s Principal Executive Offices:

600 College Road East, Suite 3200

Princeton, NJ 08540

 

Item 2(a) Name of Person Filing:

The Reporting Person is Devon Park Bioventures, L.P. Additionally, information is included herein with respect to (i) Devon Park Associates, L.P., a Delaware limited partnership and the general partner of the Reporting Person (“Devon Park Associates”), (ii) Devon Park Associates, LLC, a Delaware limited liability company and the general partner of Devon Park Associates (“Devon Park Associates, LLC”), and (iii) Charles Moller, Marc Ostro, and Devang Kantesaria, the managing members of Devon Park Associates, LLC (the “Managing Members”).

 

Item 2(b) Address of Principal Business Office or, if None, Residence:

1400 Liberty Ridge Drive, Suite 103

Wayne, PA 19087

 

Item 2(c) Citizenship:

Delaware.

 

Item 2(d) Title of Class of Securities:

Common Stock.

 

Item 2(e) CUSIP Number:

06850R108

 

Item 3. If this Statement is filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is

 

   (a)      ¨      Broker or dealer registered under Section 15 of the Exchange Act;
   (b)      ¨      Bank as defined in Section 3(a) (6) of the Exchange Act;
   (c)      ¨      Insurance company as defined in Section 3(a) (19) of the Exchange Act;
   (d)      ¨      Investment company registered under Section 8 of the Investment Company Act;
   (e)      ¨      An investment adviser in accordance with Rule 13d-1(b) (1) (ii) (E);
   (f)      ¨      An employee benefit plan or endowment fund in accordance with Rule 13d-1(b) (1) (ii) (F);
   (g)      ¨      A parent holding company or control person in accordance with Rule 13d-1(b) (1) (ii) (G);
   (h)      ¨      A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
   (i)      ¨      A church plan that is excluded from the definition of an investment company under Section 3(c) (14) of the Investment Company Act;
   (j)      ¨      Group, in accordance with Rule 13d-1(b) (1) (ii) (J).

Not applicable.


CUSIP No. 06850R108    Page 4 of 5

 

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of Common Stock of the Issuer beneficially owned by each of the Reporting Person and other persons identified in Item 2(a) herein.

 

  (a) Amount beneficially owned: -0-

 

  (b) Percent of class: 0.0%

 

  (c) Number of shares as to which the person has:

 

  (i) Sole power to vote or to direct the vote: -0-

 

  (ii) Shared power to vote or to direct the vote: -0-

 

  (iii) Sole power to dispose or to direct the disposition of: -0-

 

  (iv) Shared power to dispose or to direct the disposition of: -0-

Neither the filing of this Amendment No. 1 to Schedule 13G nor any of its contents shall be deemed to constitute an admission that each of the Managing Members is the beneficial owner of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and such beneficial ownership is expressly disclaimed.

 

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Person and each of the persons identified in Item 2(a) herein has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  x

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

 

Item 8. Identification and Classification of Members of the Group.

Not Applicable

 

Item 9. Notice of Dissolution of Group.

Not Applicable

 

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

[The remainder of this page intentionally left blank]


CUSIP No. 06850R108    Page 5 of 5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 5, 2009

 

Devon Park Bioventures, L.P., a Delaware limited partnership

By: Devon Park Associates, L.P. its general partner
By: Devon Park Associates, LLC, its general partner
/s/ Devang Kantesaria
Name: Devang Kantesaria
Title: Managing Member
-----END PRIVACY-ENHANCED MESSAGE-----